gastroparesis
Jan 28, 2025
FDA Approves LEQEMBI IV Dosing for Early Alzheimer’s; Vanda Accepts FDA Hearing on Tradipitant for Gastroparesis; Cartesian Gains FDA Protocol Approval for Myasthenia Gravis Trial; Zai Lab Secures FDA Orphan Status for DLL3 ADC in SCLC; Dyne Receives FDA Fast Track for DYNE-101 in Myotonic Dystrophy
FDA Approves LEQEMBI® (Lecanemab-Irmb) IV Maintenance Dosing for Early Alzheimer’s Disease Treatment Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb), allowing intravenous (IV) maintenance dosing every four week...
Read More...
Aug 19, 2020
Nutrition Intervention: Foods to take and foods to avoid when suffering from Gastroparesis
Gastroparesis, often referred to as delayed gastric emptying, is a disorder affecting the movement of food from the stomach to the small intestine. As per the National Institute of Diabetes and Digestive and Kidney Diseases, “Gastroparesis is not common. Out of 100,000 people, about 10 men and 40 women have gastrop...
Read More...
Aug 17, 2020
New Hopes; New Horizons: Gastroparesis Market Has Mighty Treatment Options On Its Sleeves
The Gastroparesis market size in the 7MM was found to be USD 3,170.01 million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. Gastroparesis or Delayed gastric emp...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
